Use the journals feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#41
JOURNAL ARTICLE
Taku Hatano, Renpei Sengoku, Hiroshi Nagayama, Naotake Yanagisawa, Asako Yoritaka, Keisuke Suzuki, Noriko Nishikawa, Yohei Mukai, Kyoichi Nomura, Norihito Yoshida, Morinobu Seki, Miho Kawabe Matsukawa, Hiroo Terashi, Katsuo Kimura, Jun Tashiro, Shigeki Hirano, Hidetomo Murakami, Hideto Joki, Tsuyoshi Uchiyama, Hideki Shimura, Kotaro Ogaki, Jiro Fukae, Yoshio Tsuboi, Kazushi Takahashi, Toshimasa Yamamoto, Kenichi Kaida, Ryoko Ihara, Kazutomi Kanemaru, Osamu Kano
INTRODUCTION: A higher levodopa dose is a risk factor for motor complications in Parkinson's disease (PD). Istradefylline (IST) is used as adjunctive treatment to levodopa in PD patients with off episodes, but its impact on levodopa dose titration remains unclear. The objective of this study was to investigate the effect of IST on levodopa dose escalation in PD patients with wearing-off. METHODS: This was a multicenter, open-label, randomized, parallel-group controlled study (ISTRA ADJUST PD) in which PD patients experiencing wearing-off (n = 114) who were receiving levodopa 300-400 mg/day were randomized to receive IST or no IST (control)...
January 16, 2024: Neurology and Therapy
#42
REVIEW
Mark S Freedman, Patricia K Coyle, Kerstin Hellwig, Barry Singer, Daniel Wynn, Bianca Weinstock-Guttman, Silva Markovic-Plese, Andrew Galazka, Fernando Dangond, Julie Korich, Anthony T Reder
Multiple sclerosis (MS) is a chronic, progressive, inflammatory disorder of the central nervous system. Relapsing-remitting MS (RRMS), the most common form of the disease, is characterized by transient neurological dysfunction with concurrent accumulation of disability. Over the past three decades, disease-modifying therapies (DMTs) capable of reducing the frequency of relapses and slowing disability worsening have been studied and approved for use in patients with RRMS. The first DMTs were interferon-betas (IFN-βs), which were approved in the 1990s...
January 11, 2024: Neurology and Therapy
#43
JOURNAL ARTICLE
Francesco Muntoni, Barry J Byrne, Hugh J McMillan, Monique M Ryan, Brenda L Wong, Juergen Dukart, Amita Bansal, Valerie Cosson, Roxana Dreghici, Maitea Guridi, Michael Rabbia, Hannah Staunton, Giridhar S Tirucherai, Karl Yen, Xiling Yuan, Kathryn R Wagner
INTRODUCTION: Duchenne muscular dystrophy (DMD) is a genetic muscle disorder that manifests during early childhood and is ultimately fatal. Recently approved treatments targeting the genetic cause of DMD are limited to specific subpopulations of patients, highlighting the need for therapies with wider applications. Pharmacologic inhibition of myostatin, an endogenous inhibitor of muscle growth produced almost exclusively in skeletal muscle, has been shown to increase muscle mass in several species, including humans...
January 8, 2024: Neurology and Therapy
#44
REVIEW
Sharon Stoll, Kathleen Costello, Scott D Newsome, Hollie Schmidt, Amy B Sullivan, Barry Hendin
Shared decision-making (SDM) between the patient and their healthcare provider (HCP) in developing treatment plans is increasingly recognized as central to improving treatment adherence and, ultimately, patient outcomes. In multiple sclerosis (MS), SDM is particularly crucial for optimizing treatment in a landscape that has grown more complex with the availability of newer, high-efficacy MS therapies. However, little direct evidence on the effectiveness of SDM is available to guide practice. Multiple factors, including patient age, ethnic background, perceptions, invisible MS symptoms, and psychological comorbidities can influence a patient's willingness and ability to participate in SDM...
January 5, 2024: Neurology and Therapy
#45
JOURNAL ARTICLE
Pablo Rebollo, Sofía García-López, Mónica Povedano, María G Cattinari, Mercedes Martínez-Moreno, Ángeles Terrancle, Rosana Cabello-Moruno, Juan F Vázquez-Costa
INTRODUCTION: The objective of this study is to develop a clinical tool for the evaluation and follow-up of adolescent and adult patients with 5q spinal muscular atrophy (SMA) and to design its validation. METHODS: This prospective, non-interventional study will be carried out at five centres in Spain and will include patients aged 16 years or older with a confirmed diagnosis of 5q SMA (biallelic mutation of the survival motor neuron 1 [SMN1] gene). A panel of experts made up of neurologists, physiatrists and Spanish patients' association (FundAME), participated in the design of the clinical tool...
January 5, 2024: Neurology and Therapy
#46
JOURNAL ARTICLE
Etsuko Awaki, Takao Takeshima, Yasuhiko Matsumori, Koichi Hirata, Naoki Miyazaki, Ryo Takemura, Satoshi Osaga, Yoshinori Tanizawa, Mika Komori
INTRODUCTION: The impacts of migraine on daily life, including daily activities and fundamental health indicators (sleep and mental health), have not been described in detail for people with migraine in Japan. METHODS: The cross-sectional ObserVational survey of the Epidemiology, tReatment, and Care Of MigrainE (OVERCOME [Japan]) study was conducted between July and September 2020. Impacts of migraine on housework, family/social/leisure activities, driving, and sleep were assessed using questions from the Migraine Disability Assessment (MIDAS), Migraine-Specific Quality-of-Life Questionnaire, and Impact of Migraine on Partners and Adolescent Children scales and questions developed for OVERCOME (Japan)...
January 4, 2024: Neurology and Therapy
#47
JOURNAL ARTICLE
Sunita N Misra, Randa Jarrar, John M Stern, Danielle A Becker, Enrique Carrazana, Adrian L Rabinowicz
INTRODUCTION: Although prompt treatment of status epilepticus is standard of care, the effect of timing of rescue therapy administration for seizure clusters in epilepsy remains unknown. Seizure clusters are a rare but clinically important condition, and benzodiazepines are the cornerstone rescue therapy for seizure clusters in epilepsy. We characterized temporal patterns from a large dataset of treated seizure clusters in the safety study of diazepam nasal spray. METHODS: This post hoc analysis used timing data of treated seizure clusters recorded by care partners and patients in seizure diaries during a 1-year safety study...
January 4, 2024: Neurology and Therapy
#48
JOURNAL ARTICLE
Luis Genis-Najera, Maria Elena Sañudo-Maury
INTRODUCTION: The prevalence of neurological disorders is high among the Mexican population. Clonazepam is primarily indicated to treat panic disorders, certain kinds of epilepsy such as status epilepticus, childhood motor seizures (petit mal absence, Lennox-Gastaut syndrome, and infantile spasms), anxiety, and muscle spasm. This study was performed to compare bioequivalence between two oral tablet formulations of clonazepam 2 mg in healthy Mexican volunteers under fasting conditions...
December 2, 2023: Neurology and Therapy
#49
JOURNAL ARTICLE
Rita Sattler, Bryan J Traynor, Janice Robertson, Ludo Van Den Bosch, Sami J Barmada, Clive N Svendsen, Matthew D Disney, Tania F Gendron, Philip C Wong, Martin R Turner, Adam Boxer, Suma Babu, Michael Benatar, Michael Kurnellas, Jonathan D Rohrer, Christopher J Donnelly, Lynette M Bustos, Kendall Van Keuren-Jensen, Penny A Dacks, Marwan N Sabbagh
A summit held March 2023 in Scottsdale, Arizona (USA) focused on the intronic hexanucleotide expansion in the C9ORF72 gene and its relevance in frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS; C9ORF72-FTD/ALS). The goal of this summit was to connect basic scientists, clinical researchers, drug developers, and individuals affected by C9ORF72-FTD/ALS to evaluate how collaborative efforts across the FTD-ALS disease spectrum might break down existing disease silos. Presentations and discussions covered recent discoveries in C9ORF72-FTD/ALS disease mechanisms, availability of disease biomarkers and recent advances in therapeutic development, and clinical trial design for prevention and treatment for individuals affected by C9ORF72-FTD/ALS and asymptomatic pathological expansion carriers...
December 2023: Neurology and Therapy
#50
REVIEW
Arthur Esquer, Frédéric Blanc, Nicolas Collongues
INTRODUCTION: Alzheimer's disease (AD) is the most common cause of dementia worldwide, making it a major public health issue. Anti-amyloid and anti-tau antibodies are the most advanced therapeutic approach at present. Three drugs (lecanemab, donanemab and aducanumab) are on track to be marketed in the coming months. In this systematic review, we review all Phase 2 and Phase 3 clinical trials conducted in this indication and the particularities of the molecules tested. METHODS: The PubMed and ClinicalTrials...
December 2023: Neurology and Therapy
#51
JOURNAL ARTICLE
Russell Rosenberg, Rogelio Braceras, Wayne Macfadden, Shawn Candler, Jed Black, Chad Ruoff
Narcolepsy is associated with disrupted nighttime sleep (DNS). Sodium oxybate (SXB; Xyrem® ), administered twice nightly, is indicated for the treatment of cataplexy and excessive daytime sleepiness in patients 7 years or older with narcolepsy. Recently, low-sodium oxybate (LXB, Xywav® ; for people 7 years of age and older), which contains 92% less sodium than SXB and is dosed twice nightly, and sodium oxybate for extended release (SXB-ER; Lumryz™; for adults), which contains equal sodium to SXB and is dosed once nightly, have also been approved to treat cataplexy or excessive daytime sleepiness in narcolepsy...
December 2023: Neurology and Therapy
#52
JOURNAL ARTICLE
Xiaoling Pan, Yingjian Pei, Meixia Zhang, Wansi Zhong, Jin Hu, Zhimin Wang, Dongjuan Xu, Min Lou, Hongfang Chen, Zhicai Chen
INTRODUCTION: This study aimed to investigate the association between atrial fibrillation (AF), particularly newly diagnosed AF, and remote intracerebral hemorrhage (rICH) in patients with ischemic stroke who were treated with intravenous thrombolysis (IVT). METHODS: This observational study was conducted on patients with ischemic stroke who received IVT with recombinant tissue-type plasminogen activator. The data were taken from a multicenter prospective registry of a Chinese population...
November 30, 2023: Neurology and Therapy
#53
JOURNAL ARTICLE
Huijuan Wan, Qi Liu, Chao Chen, Wenyu Dong, Shengsong Wang, Weixiong Shi, Chengyu Li, Jiechuan Ren, Zhanxiang Wang, Tao Cui, Xiaoqiu Shao
INTRODUCTION: Cognitive impairment (CI) is a common comorbidity in patients with late-onset epilepsy of unknown origin (LOEU). However, limited data are available on effective screening methods for CI at an early stage. We aimed to develop and internally validate a nomogram for identifying patients with LOEU at risk of CI and investigate the potential moderating effect of education on the relationship between periventricular white matter hyperintensities (PVHs) and cognitive function...
November 29, 2023: Neurology and Therapy
#54
Pierre Clavelou, Giovanni Castelnovo, Valérie Pourcher, Jerome De Sèze, Patrick Vermersch, Ali-Frederic Ben-Amor, Carine Savarin, Gilles Defer
No abstract text is available yet for this article.
November 20, 2023: Neurology and Therapy
#55
JOURNAL ARTICLE
Sandra Parawira, Victoria Reese
Multiple sclerosis (MS) can affect people from all racial and ethnic backgrounds, but, historically, the incidence of MS in the United States was thought to be highest in White individuals. More recent data suggest that the incidence of MS in Black or African American individuals is comparable to that in White individuals. In Hispanic or Latino individuals, incidence of MS is lower, but age of onset may be earlier compared with White individuals. Additionally, there are important differences in MS disease severity, disease progression, and mortality in Black or African American and Hispanic or Latino populations...
November 20, 2023: Neurology and Therapy
#56
LETTER
Jessica Braid
No abstract text is available yet for this article.
November 4, 2023: Neurology and Therapy
#57
JOURNAL ARTICLE
Richard B Lipton, Janette Contreras-De Lama, Daniel Serrano, Ella Engstrom, Nicolai D Ayasse, Weijie Poh, François Cadiou, Aubrey Manack Adams
INTRODUCTION: Although acute and preventive treatments for migraine are commonly given in combination, data on the real-world effectiveness of ubrogepant as an acute treatment when used with an anti-calcitonin gene-related peptide (CGRP) monoclonal antibody (with or without onabotulinumtoxinA) are limited. This analysis sought to evaluate the real-world effectiveness, treatment satisfaction, and optimization of ubrogepant for the acute treatment of migraine when used in combination with an anti-CGRP monoclonal antibody, with or without concomitant onabotulinumtoxinA...
November 1, 2023: Neurology and Therapy
#58
JOURNAL ARTICLE
Leigh F Callahan, Brian Samsell, Dana DiBenedetti, Terry Frangiosa, Christina Slota, Virginia Biggar, Russ Paulsen, Debra Lappin, William L Herring, Carla Romano
INTRODUCTION: Non-professional care partners play an important and often evolving role in the care of persons living with Alzheimer's disease (PLWAD). We investigated two elements of the care partner experience, namely time and strain incurred by care partners providing care to PLWAD across the severity spectrum. METHODS: Data gathered from the Alzheimer's Disease Patient and Caregiver Engagement (AD PACE) What Matters Most (WMM) study series were analyzed to determine how much time care partners spent providing care to PLWAD based on where the care recipients lived...
October 27, 2023: Neurology and Therapy
#59
JOURNAL ARTICLE
Shigeyuki Tahara, Fumio Otsuka, Takaaki Endo
INTRODUCTION: Individuals with traumatic brain injury (TBI) or subarachnoid hemorrhage (SAH) are at a high risk of hypopituitarism, and should benefit from early diagnosis and management. However, data on awareness, attitudes, and practices of physicians treating hypopituitarism post-TBI/SAH are limited. The objectives of this study were to gain an understanding of the awareness of Japanese neurosurgeons and endocrinologists towards hypopituitarism post-TBI/SAH and the need for pituitary function assessments in these patients; and to assess the practices and perspectives of these specialists on screening patients with this condition...
October 24, 2023: Neurology and Therapy
#60
JOURNAL ARTICLE
José E Meca-Lallana, José M Prieto González, Ana B Caminero Rodríguez, Javier Olascoaga Urtaza, Ana M Alonso, Eduardo Durán Ferreras, Raúl Espinosa, Julio Dotor, Mercedes Romera, Adrián Ares Luque, Domingo Pérez Ruiz, Carmen Calles, Miguel A Hernández, Miguel Hervás García, Amelia Mendoza Rodríguez, Yasmina Berdei Montero, Nieves Téllez, Nicolás Herrera Varó, Javier Sotoca, Silvia Presas-Rodríguez, Luis A Querol Gutierrez, Mariona Hervás Pujol, Jordi Batlle Nadal, Gisela Martín Ozaeta, Laura Gubieras Lillo, Sergio Martínez Yélamos, Lluís Ramió-Torrentà, Javier Mallada Frechin, Antonio Belenguer Benavides, Francisco Gascón-Giménez, Bonaventura Casanova, Lamberto Landete Pascual, Leticia Berenguer, Laura Navarro, Montserrat Gómez Gutierrez, Carmen Durán, Ana Rodríguez Regal, Elena Álvarez, Daniel A García-Estévez, Ana M López Real, Miguel A Llaneza González, María E Marzo Sola, José L Sánchez-Menoyo, Agustín Oterino, Ramón Villaverde González, Tamara Castillo-Triviño, Amaya Álvarez de Arcaya, Cristina Llarena
INTRODUCTION: Teriflunomide is a once-daily oral immunomodulator approved for relapsing forms of multiple sclerosis (MS) or relapsing-remitting multiple sclerosis (RRMS; depending on the local label), based on extensive evidence from clinical trials and a real-world setting on efficacy, tolerability and patient-reported benefits. The TERICARE study assessed the impact of teriflunomide treatment over 2 years on health-related quality of life (HRQoL) and some of the most common and disabling symptoms of MS, such as fatigue and depression...
October 20, 2023: Neurology and Therapy
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
